Location: Chicago, United States
Date: May 31 to June 4
American Society of Clinical Oncology.
Immunotherapies in Thymic Malignancies
Prof. Heather A. Wakelee speaks about the use of checkpoint inhibitors in Thymic Malignancies.
Will There Ever Be Progress for Leptomeningeal Carcinomatosis: An Update on the Multidisciplinary Management in the Setting of Immuno-Oncology and Precision Medicine
Highlights of prostate cancer research at ASCO2019
A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma
Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.
To Infinity and Beyond: The Future of Immunotherapy in Gynecologic Malignancies
Hematologic Malignancies—Plasma Cell Dyscrasia
ANNOUNCE: A randomized, placebo-controlled, double-blind, phase III trial of doxorubicin + olaratumab versus dox + PBO in patients with advanced soft tissue sarcomas
Targeting Breast Cancer: Breaking the Code
Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.
Should Immunotherapy Change the Practice for Esophageal and Gastric Cancer in the Near Future?
Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275
Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.
Highlights of the Metastatic Breast Cancer Session
Antiangiogenic and Targeted Therapies With or Without Anti-PD1/Anti-PD-L1